This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $80.62, marking a +1.82% move from the previous day.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare
by Zacks Equity Research
MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.
Medtronic (MDT) to Enhance AI Innovation With New Platform
by Zacks Equity Research
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
Why Is Medtronic (MDT) Down 6.1% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic's (MDT) Affera Ablation System Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Medtronic, Illinois Tool Works and Fiserv
by Zacks Equity Research
Microsoft, Alibaba Group, Medtronic, Illinois Tool Works and Fiserv are part of the Zacks top Analyst Blog.
Top Stock Reports for Microsoft, Alibaba & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Alibaba Group Holding Limited (BABA) and Medtronic plc (MDT).
Abbott (ABT) Makes Progress in the TAVI Space With Navitor
by Zacks Equity Research
Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Abbott's (ABT) MitraClip Device Shows Favorable Outcome
by Zacks Equity Research
Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.
Beat the Market the Zacks Way: Oracle, Medtronic, Uber in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Medtronic's (MDT) MiniMed 780G System Shows Favorable Results
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system was designed to forecast real-life requirements where carbohydrate counts aren't always exact and meal doses are often missed.
Company News for Feb 22, 2023
by Zacks Equity Research
Companies In The News Are: WMT, HD, MDT, TAP.
Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.
Medtronic (MDT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended January 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic (MDT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 2.76%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Medtronic (MDT) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $84.20 in the latest trading session, marking a -0.34% move from the prior day.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $83.69, moving +0.1% from the previous trading session.
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.
The Zacks Analyst Blog Highlights HCA Healthcare, Booz Allen Hamilton, GATX, NXP Semiconductors and MSCI
by Zacks Equity Research
HCA Healthcare, Booz Allen Hamilton, GATX, NXP Semiconductors and MSCI are included in this Analyst Blog.